Whats new

Whats new.

Baird - First Patient Dosed in Phase 3 TACTI-004 for Efti Combo in 1L NSCLC; Rated OP, US$7 PT (Analyst: Colleen Kusy)

March 25th 2025

For a copy of this research report please contact your Baird advisor

Go back